Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Qyuns Therapeutics’ Partner Caldera to Merge with Synlogic in $278M Backed Deal, Advancing TL1A/IL-23p19 Bispecific Antibody for Inflammatory Bowel Disease

Fineline Cube Jul 30, 2026
Company Deals

China Resources Pharmaceutical to Acquire Lier Chemical for $795M in Strategic Move into Agrochemical Sector

Fineline Cube Jul 30, 2026
Company Deals

TPMeds Secures Tens of Millions in RMB Angel Round Led by Lotus Lake Ventures to Advance TPM004 IND and PepTetris Platform

Fineline Cube Jul 29, 2026
Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026
Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Fineline Cube Jul 28, 2026
Policy / Regulatory

China’s CDE Tightens Drug Review Standards with New “No Supplemental Data” Rule for Major Deficiencies

Fineline Cube Jul 29, 2026
Company Drug

Buchang Pharmaceuticals Withdraws Efperepoetin Alfa Registration Application for CKD Anemia Due to Dossier Enhancement Requirements

Fineline Cube Jul 30, 2026
Company Drug

Hengrui Pharmaceuticals’ HER3-Targeting ADC Ruzaltatug Rezetecan Receives NMPA Marketing Application Acceptance for EGFR-Mutant NSCLC Post-TKI Progression

Fineline Cube Jul 30, 2026
Company Drug

Dizal Pharmaceutical Presents Positive Trial Data for Golidocitinib at ASH Annual Meeting

Fineline Cube Dec 13, 2023

China-based Dizal Pharmaceutical Co., Ltd, (SHA: 688192), a spin-off from AstraZeneca (AZ, NASDAQ: AZN) China...

Company Drug

China Medical System Gets NMPA Green Light for Phase III Vitiligo Study with Ruxolitinib Cream

Fineline Cube Dec 13, 2023

China Medical System Holdings (CMS; HKG: 0867) has announced that it has received approval from...

Company Drug

CARsgen Therapeutics Halts Clinical Studies for Three CAR-T Therapies in the US Following FDA Request

Fineline Cube Dec 13, 2023

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced that the US Food and Drug...

Company Drug

Shanghai Henlius Biotech Submits Another Application for Serplulimab in China

Fineline Cube Dec 13, 2023

Shanghai Henlius Biotech Inc., (HKG: 2696) has announced a new market filing for its anti-programmed...

Company Drug

Clover Biopharmaceuticals Commences Phase I Trial for RSV Vaccine in Australia

Fineline Cube Dec 13, 2023

China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) has announced the successful enrollment of the first batch...

Company Drug

HutchMed’s Elunate-Tyvyt Combination Study for Renal Cell Carcinoma Completes Enrollment

Fineline Cube Dec 13, 2023

China-based HutchMed (NASDAQ: HCM) has announced the completion of patient enrollment in its Phase II/III...

Company Drug

Luye Pharma’s Lurbinectedin Receives Market Approval in Hong Kong for SCLC Treatment

Fineline Cube Dec 13, 2023

China-based Luye Pharma Group (HKG: 2186) has announced that Hong Kong’s pharmacy and poisons board...

Company Drug

Suzhou OSAI Biopharma’s L. crispatus Capsule Meets Phase III Endpoints in Bacterial Vaginosis Study

Fineline Cube Dec 13, 2023

China-based Suzhou OSAI Biopharma Inc., a specialist in live biotherapeutic products (LBPs), has announced that...

Company Drug

Sanofi Abandons MZE001 Licensing Deal Following FTC Intervention Over Pompe Disease Monopoly Concerns

Fineline Cube Dec 12, 2023

Sanofi (NASDAQ: SNY) has withdrawn from an agreement announced earlier this year to in-license the...

Company Drug

BMS Advances TIGITxCD96 Bispecific Antibody into Phase II Dose Expansion

Fineline Cube Dec 12, 2023

Bristol Myers Squibb (BMS; NYSE: BMY) has advanced its development program for the TIGITxCD96 bispecific...

Company Deals

Sanofi Partners with Minapharm for Local Production of Anticoagulant Clexane in Egypt

Fineline Cube Dec 12, 2023

Sanofi (NASDAQ: SNY) has entered into a partnership with Egyptian biotechnology company Minapharm to locally...

Company Drug

Sisram Medical’s Profhilo Accepted for Review by China’s NMPA

Fineline Cube Dec 12, 2023

Sisram Medical Ltd (HKG: 1696), an Israel-based company within the Fosun Pharmaceutical Group (SHA: 600196),...

Company Drug

Staidson Pharmaceutical Initiates Clinical Study for ARDS Treatment STSA-1002

Fineline Cube Dec 12, 2023

Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a Chinese pharmaceutical company, has announced the dosing...

Company Medical Device

Cryofocus Medtech Receives NMPA Approval for Complete Cardiac Cryoablation System

Fineline Cube Dec 12, 2023

Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922), a Shanghai-based specialist in cryoablation treatment, has announced...

Company Drug

Staidson Pharmaceutical Halts Clinical Trial for Hepatitis B Drug Due to Efficacy Concerns

Fineline Cube Dec 12, 2023

Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a Chinese pharmaceutical company, has announced the cancellation...

Company Medical Device

Zylox-Tonbridge Medical Technology’s ZENFLOW T18 Receives NMPA Marketing Approval

Fineline Cube Dec 12, 2023

Zylox-Tonbridge Medical Technology (HKG: 2190), a developer of nerve and peripheral vascular interventional devices based...

Company Drug

Skyline Therapeutics’ Gene Therapy SKG0201 for SMA Gets Green Light from China’s NMPA

Fineline Cube Dec 12, 2023

Skyline Therapeutics has received clinical trial approval from China’s National Medical Products Administration (NMPA) for...

Company Deals

Sichuan Biokin and Bristol Myers Squibb Ink USD 8.4 Billion Licensing Deal for ADC Candidate

Fineline Cube Dec 12, 2023

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a Chinese pharmaceutical company, has announced a landmark...

Company Deals

Kangtai Biological Partners with Gennvax Egypt to Commercialize 13-Valent Pneumococcal Vaccine

Fineline Cube Dec 12, 2023

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a Chinese biopharmaceutical company, has entered into...

Company Deals

Haplox and Illumina Mark Milestone with Production of NextSeq 2000Dx-CN-HAP Sequencing System in China

Fineline Cube Dec 12, 2023

Haplox Biotechnology Co., Ltd, a Chinese biotech firm, and US industry leader Illumina (NASDAQ: ILMN)...

Posts pagination

1 … 466 467 468 … 701

Recent updates

  • Qyuns Therapeutics’ Partner Caldera to Merge with Synlogic in $278M Backed Deal, Advancing TL1A/IL-23p19 Bispecific Antibody for Inflammatory Bowel Disease
  • Buchang Pharmaceuticals Withdraws Efperepoetin Alfa Registration Application for CKD Anemia Due to Dossier Enhancement Requirements
  • Hengrui Pharmaceuticals’ HER3-Targeting ADC Ruzaltatug Rezetecan Receives NMPA Marketing Application Acceptance for EGFR-Mutant NSCLC Post-TKI Progression
  • Huahai Pharmaceutical’s Anti-IL-36R Antibody Huayijing Receives NMPA Priority Review Approval for Generalized Pustular Psoriasis Flares
  • CSPC Pharmaceutical’s Nectin-4 Targeting ADC CRB-701 Receives FDA Approval for Registrational Trial in Second-Line Oropharyngeal Squamous Cell Carcinoma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Qyuns Therapeutics’ Partner Caldera to Merge with Synlogic in $278M Backed Deal, Advancing TL1A/IL-23p19 Bispecific Antibody for Inflammatory Bowel Disease

Company Drug

Buchang Pharmaceuticals Withdraws Efperepoetin Alfa Registration Application for CKD Anemia Due to Dossier Enhancement Requirements

Company Drug

Hengrui Pharmaceuticals’ HER3-Targeting ADC Ruzaltatug Rezetecan Receives NMPA Marketing Application Acceptance for EGFR-Mutant NSCLC Post-TKI Progression

Company Drug

Huahai Pharmaceutical’s Anti-IL-36R Antibody Huayijing Receives NMPA Priority Review Approval for Generalized Pustular Psoriasis Flares

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.